MCID: TYS001
MIFTS: 71

Tay-Sachs Disease

Categories: Genetic diseases, Rare diseases, Metabolic diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Tay-Sachs Disease

MalaCards integrated aliases for Tay-Sachs Disease:

Name: Tay-Sachs Disease 53 37 12 72 49 24 50 55 71 36 28 51 40 41 14 69
Hexosaminidase a Deficiency 53 12 23 49 24 55 71
Hexa Deficiency 53 49 24 71
Tsd 53 49 24 71
Hexosaminidase Alpha-Subunit Deficiency 49 24 69
Gm2-Gangliosidosis, Several Forms 53 13
B Variant Gm2 Gangliosidosis 49 24
Sphingolipidosis, Tay-Sachs 49 24
Gm2 Gangliosidosis, Type 1 49 24
Gm2 Gangliosidosis 23 51
Tay-Sachs Disease, Pseudo-Ab Variant 28
Tay-Sachs Disease Pseudo-Ab Variant 71
Gm2 Gangliosidosis, B, B1 Variant 55
B Variant Gm2-Gangliosidosis 53
Gm2-Gangliosidosis B Variant 71
Tay-Sachs Disease Variant B1 71
Gangliosidosis Gm2 , Type 1 49
Gm2-Gangliosidosis, Type I 53
Hex a Pseudodeficiency 53
Gm2-Gangliosidosis 1 71
Gangliosidoses, Gm2 69
Disease, Tay-Sachs 12
Hex a Deficiency 23
Gm2g1 71

Characteristics:

Orphanet epidemiological data:

55
tay-sachs disease
Inheritance: Autosomal recessive; Prevalence: 1-5/10000,1-9/1000000 (Europe),1-9/100000 (Portugal),1-9/1000000 (Czech Republic),1-9/1000000 (Australia),1-9/1000000 (Worldwide),1-9/1000000 (Netherlands),1-9/1000000 (Canada),1-9/1000000 (United Arab Emirates),1-9/1000000 (Turkey),1-9/1000000 (Sweden); Age of onset: All ages; Age of death: any age;

OMIM:

53
Inheritance:
autosomal recessive

Miscellaneous:
infantile onset
usually fatal by age 5 years
incidence of 1 in 3,900 births among jewish persons
incidence of 1 in 320,000 births among non-jewish persons


HPO:

31
tay-sachs disease:
Onset and clinical course infantile onset
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Tay-Sachs Disease

NIH Rare Diseases : 49 Tay-Sachs disease is a rare, inheritedneurodegenerative disease. People with Tay-Sachs disease do not have enough of an enzyme called beta-hexosaminidase A.  The less enzyme a person has, the more severe the disease and the earlier that symptoms appear. There are 3 forms of Tay-Sachs disease, distinguished by the general age of onset:Infantile - the most common severe form, with symptoms appearing in the first few months of life. Symptoms include a loss of skills learned (regression), seizures, and loss of muscle and mental functions. Children with this form do not survive past early childhood. Juvenile - a form with a range of severity, with symptoms appearing any time during childhood (but usually between ages 2 and 5). Symptoms include behavior problems, gradual loss of skills, frequent respiratory infections, and seizures. People with this form typically do not survive past their teenage years. Late onset/adult - the least severe form, with symptoms appearing in late childhood to adulthood. Symptoms may include clumsiness, muscle weakness, psychiatric disorders, and gradual loss of skills, often leading to the need for mobility assistance. Intellect and behavior become impaired in some cases. The lifespan varies from shortened to unaffected. Tay-Sachs disease is caused by mutations in the HEXA gene and inheritance is autosomal recessive. The HEXA gene gives the body instructions to make part of the beta-hexosaminidase A enzyme, which is needed to break down a substance called GM2 ganglioside. When the enzyme is not functional or not made, GM2 ganglioside builds up in the nerve cells (neurons) of the brain and spinal cord, causing the symptoms of the disease. The diagnosis of Tay-Sachs disease involves a blood test that detects absent or very low levels of beta-hexosaminidase A enzyme activity. Molecular genetic testing of the HEXA gene may be used to identify the specific mutations present, or to rule out the disease if a false-positive blood test result is suspected. Currently there is no cure for Tay-Sachs disease, and there are no therapies that slow the progression of the disease. Treatment aims to relieve symptoms and increase quality of life. For example, children with seizures may be treated with anti-seizure medicines. Adequate nutrition and hydration are recommended, to prevent complications.Note: You may also find Tay-Sachs disease referred to as a lysosomal storage disease or a GM2-gangliosidosis because the disease involves a lysosomal enzyme and the buildup of GM2 ganglioside. Last updated: 1/22/2018

MalaCards based summary : Tay-Sachs Disease, also known as hexosaminidase a deficiency, is related to gm2-gangliosidosis, ab variant and sandhoff disease, and has symptoms including ataxia, seizures and macrocephaly. An important gene associated with Tay-Sachs Disease is HEXA (Hexosaminidase Subunit Alpha), and among its related pathways/superpathways are Glycosaminoglycan degradation and Other glycan degradation. The drugs Miglustat and 1-Deoxynojirimycin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and spinal cord, and related phenotypes are behavior/neurological and nervous system

Genetics Home Reference : 24 Tay-Sachs disease is a rare inherited disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord.

OMIM : 53 Tay-Sachs disease is an autosomal recessive, progressive neurodegenerative disorder which, in the classic infantile form, is usually fatal by age 2 or 3 years. (272800)

MedlinePlus : 40 Tay-Sachs disease is a rare, inherited disease. It is a type of lipid metabolism disorder. It causes too much of a fatty substance to build up in the brain. This buildup destroys nerve cells, causing mental and physical problems. . Infants with Tay-Sachs disease appear to develop normally for the first few months of life. Then mental and physical abilities decline. The child becomes blind, deaf, and unable to swallow. Muscles begin to waste away and paralysis sets in. Even with the best of care, children with Tay-Sachs disease usually die by age 4. The cause is a gene mutation which is most common in Eastern European Ashkenazi Jews. To get the disease, both parents must have the gene. If they do, there is a 25% chance of the child having the disease. A blood test and prenatal tests can check for the gene or the disease. There is no cure. Medicines and good nutrition can help some symptoms. Some children need feeding tubes. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 50 Tay-Sachs disease is a inherited metabolic disease caused by the harmful buildup of lipids (fatty materials such as oils and acids) in various cells and tissues in the body.  It is part of a group of genetic disorders called the GM2 gangliosidoses.  Tay-Sachs and its variant form are caused by a deficiency in the enzyme hexosaminidase A.  Affected children appear to develop normally until about age 6 months.  Then, symptoms begin and include progressive loss of mental ability, dementia, blindness, increased startle reflex to noise, progressive loss of hearing leading to deafness, and difficulty with swallowing.  Seizures may begin in the child's second year. Persons with Tay-Sachs also have "cherry-red" spots in their eyes.  A much rarer form of the disorder, called late-onset Tay-Sachs disease, occurs in individuals in their twenties and early thirties and is characterized by an unsteady gait and progressive neurological deterioration. The incidence of Tay-Sachs has been particularly high among people of Eastern European and Askhenazi Jewish descent., as well as in certain French Canadians and Louisiana Cajuns. Affected individuals and carriers of Tay-Sachs disease can be identified by a blood test that measures hexosaminidase A activity. Both parents must carry the mutated gene in order to have an affected child. In these instances, there is a 25 percent chance with each pregnancy that the child will be affected with Tay-Sachs disease. Prenatal diagnosis is available if desired.  A very severe form of Tay-Sachs disease is know as Sandhoff disease, which is not limited to any ethnic group.

UniProtKB/Swiss-Prot : 71 GM2-gangliosidosis 1: An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

GeneReviews: NBK1218

Related Diseases for Tay-Sachs Disease

Diseases in the Tay-Sachs Disease family:

Tay-Sachs Disease, B Variant, Juvenile Form Tay-Sachs Disease, B Variant, Infantile Form
Tay-Sachs Disease, B1 Variant Tay-Sachs Disease, B Variant, Adult Form

Diseases related to Tay-Sachs Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 gm2-gangliosidosis, ab variant 33.6 GM2A MGEA5
2 sandhoff disease 31.8 GM2A HEXA HEXB HHEX MGEA5
3 metachromatic leukodystrophy 30.6 ARSA HEXA PSAP
4 sphingolipidosis 30.6 ARSA CTSA HEXA HEXB MGEA5 PSAP
5 tay-sachs disease, b1 variant 12.5
6 gm2 gangliosidosis, 0 variant 12.3
7 tay-sachs disease, b variant, juvenile form 12.3
8 tay-sachs disease, b variant, infantile form 12.3
9 tay-sachs disease, b variant, adult form 12.3
10 gm1-gangliosidosis, type i 11.2
11 lipid metabolism disorder 11.2
12 floppy infant syndrome 11.2
13 generalized gangliosidoses 11.2
14 hypotonia 11.2
15 infantile hypotonia 11.2
16 cystic fibrosis 10.5
17 cerebritis 10.4
18 neuronitis 10.4
19 fibrosis of extraocular muscles, congenital, 1 10.3
20 thalassemia 10.3
21 leukodystrophy 10.3
22 metachromatic leukodystrophy, adult form 10.3 ARSA PSAP
23 metachromatic leukodystrophy, late infantile form 10.3 ARSA PSAP
24 metachromatic leukodystrophy, juvenile form 10.3 ARSA PSAP
25 blood group, i system 10.2
26 pick disease of brain 10.2
27 beta-thalassemia 10.2
28 sickle cell disease 10.2
29 mannosidosis, alpha b, lysosomal 10.2 CTSA HEXA
30 myoclonic cerebellar dyssynergia 10.1 CTSA VIM
31 gangliosidosis gm1 10.1 HEXA NEU1 PSAP
32 fucosidosis 10.1 CTSA HEXA
33 lipid storage disease 10.1 ARSA HEXA PSAP
34 alzheimer disease 10.1
35 coloboma of macula 10.1
36 hexosaminidase c 10.1
37 prader-willi syndrome 10.1
38 schizophrenia 10.1
39 friedreich ataxia 1 10.1
40 phenylketonuria 10.1
41 fabry disease 10.1
42 ataxia and polyneuropathy, adult-onset 10.1
43 aging 10.1
44 macular degeneration, age-related, 1 10.1
45 polyglucosan body myopathy 1 with or without immunodeficiency 10.1
46 niemann-pick disease 10.1
47 thrombocytopenia 10.1
48 autosomal recessive disease 10.1
49 stuttering 10.1
50 ptosis 10.1

Graphical network of the top 20 diseases related to Tay-Sachs Disease:



Diseases related to Tay-Sachs Disease

Symptoms & Phenotypes for Tay-Sachs Disease

Symptoms via clinical synopsis from OMIM:

53
Neurologic Central Nervous System:
seizures
dementia
poor head control
hypotonia
increased startle response
more
Respiratory Airways:
aspiration

Laboratory Abnormalities:
ballooned neurons
gm2-ganglioside accumulation
hexosaminidase a deficiency

Head And Neck Eyes:
blindness
macular pallor with prominence of fovea centralis (cherry red spot)

Neurologic Behavioral Psychiatric Manifestations:
apathy


Clinical features from OMIM:

272800

Human phenotypes related to Tay-Sachs Disease:

55 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001251
2 seizures 55 31 hallmark (90%) Very frequent (99-80%) HP:0001250
3 macrocephaly 55 31 hallmark (90%) Very frequent (99-80%) HP:0000256
4 muscular hypotonia 55 31 frequent (33%) Frequent (79-30%) HP:0001252
5 spasticity 55 31 frequent (33%) Frequent (79-30%) HP:0001257
6 hyperreflexia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001347
7 eeg abnormality 55 31 hallmark (90%) Very frequent (99-80%) HP:0002353
8 developmental regression 55 31 hallmark (90%) Very frequent (99-80%) HP:0002376
9 hearing impairment 55 31 hallmark (90%) Very frequent (99-80%) HP:0000365
10 global developmental delay 55 31 hallmark (90%) Very frequent (99-80%) HP:0001263
11 splenomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0001744
12 recurrent respiratory infections 55 31 frequent (33%) Frequent (79-30%) HP:0002205
13 hepatomegaly 55 31 frequent (33%) Frequent (79-30%) HP:0002240
14 optic atrophy 55 31 frequent (33%) Frequent (79-30%) HP:0000648
15 blindness 55 31 hallmark (90%) Very frequent (99-80%) HP:0000618
16 cherry red spot of the macula 55 31 hallmark (90%) Very frequent (99-80%) HP:0010729
17 abnormality of movement 55 31 hallmark (90%) Very frequent (99-80%) HP:0100022
18 myotonia 55 31 frequent (33%) Frequent (79-30%) HP:0002486
19 hemiplegia/hemiparesis 55 31 hallmark (90%) Very frequent (99-80%) HP:0004374
20 intellectual disability, progressive 55 31 hallmark (90%) Very frequent (99-80%) HP:0006887
21 psychomotor deterioration 55 31 hallmark (90%) Very frequent (99-80%) HP:0002361
22 increased muscle lipid content 55 31 hallmark (90%) Very frequent (99-80%) HP:0009058
23 visual impairment 55 Very frequent (99-80%)
24 dementia 31 HP:0000726
25 aspiration 31 HP:0002835
26 apathy 31 HP:0000741
27 generalized hypotonia 31 HP:0001290
28 poor head control 31 HP:0002421
29 exaggerated startle response 31 HP:0002267
30 gm2-ganglioside accumulation 31 HP:0003495

UMLS symptoms related to Tay-Sachs Disease:


sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

MGI Mouse Phenotypes related to Tay-Sachs Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 HEXB NEU1 ARSA PSAP CTSA GM2A
2 nervous system MP:0003631 9.86 HEXA HEXB HHEX NEU1 ARSA PSAP
3 liver/biliary system MP:0005370 9.8 HEXB HHEX NEU1 PSAP CTSA HEXA
4 renal/urinary system MP:0005367 9.55 HEXA HEXB NEU1 CTSA PSAP
5 respiratory system MP:0005388 9.43 HHEX MGEA5 NEU1 PSAP CTSA VIM
6 vision/eye MP:0005391 9.1 VIM HEXA HEXB HHEX NEU1 PSAP

Drugs & Therapeutics for Tay-Sachs Disease

Drugs for Tay-Sachs Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miglustat Approved Phase 4,Phase 3,Phase 2 72599-27-0 51634
2
1-Deoxynojirimycin Experimental Phase 4,Phase 3,Phase 2 19130-96-2 1374
3 Anti-HIV Agents Phase 4,Phase 3,Phase 2
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
5 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
6 Antiviral Agents Phase 4,Phase 3,Phase 2
7 Cardiac Glycosides Phase 4,Phase 3,Phase 2
8 Glycoside Hydrolase Inhibitors Phase 4,Phase 3,Phase 2
9 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
10
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
14 Alkylating Agents Phase 2, Phase 3
15 Antilymphocyte Serum Phase 2, Phase 3
16 Antirheumatic Agents Phase 2, Phase 3
17 Immunosuppressive Agents Phase 2, Phase 3
18 Methylprednisolone acetate Phase 2, Phase 3
19 Methylprednisolone Hemisuccinate Phase 2, Phase 3
20 Prednisolone acetate Phase 2, Phase 3
21 Prednisolone hemisuccinate Phase 2, Phase 3
22 Prednisolone phosphate Phase 2, Phase 3
23
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
24
alemtuzumab Approved, Investigational Phase 2 216503-57-0
25
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
26
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
27
Hydroxyurea Approved Phase 2 127-07-1 3657
28
Melphalan Approved Phase 2 148-82-3 460612 4053
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
31
leucovorin Approved, Nutraceutical Phase 1, Phase 2 58-05-9 143 6006
32 tannic acid Approved, Nutraceutical Phase 2
33 Antimalarials Phase 1, Phase 2
34 Antiparasitic Agents Phase 1, Phase 2
35 Antiprotozoal Agents Phase 1, Phase 2
36 Folic Acid Antagonists Phase 1, Phase 2
37 Vitamin B Complex Phase 1, Phase 2
38 Antifungal Agents Phase 2
39 Antimetabolites Phase 2
40 Antimetabolites, Antineoplastic Phase 2
41 Calcineurin Inhibitors Phase 2
42 Cyclosporins Phase 2
43 Dermatologic Agents Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 2
45 Folate Nutraceutical Phase 1, Phase 2
46 Vitamin B9 Nutraceutical Phase 1, Phase 2
47
Mycophenolate mofetil Approved, Investigational 128794-94-5 5281078
48
Mycophenolic acid Approved 24280-93-1 446541
49 Anti-Bacterial Agents
50 Antibiotics, Antitubercular

Interventional clinical trials:

(show all 20)

# Name Status NCT ID Phase Drugs
1 Synergistic Enteral Regimen for Treatment of the Gangliosidoses Recruiting NCT02030015 Phase 4 miglustat
2 Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses Completed NCT00672022 Phase 3 Zavesca (Miglustat)
3 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
4 ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases Terminated NCT00654433 Phase 3
5 Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) Completed NCT01102686 Phase 1, Phase 2 Pyrimethamine;Leucovorin
6 Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed NCT00418847 Phase 2 miglustat
7 HSCT for High Risk Inherited Inborn Errors Completed NCT00383448 Phase 2 Clofarabine;Melphalan;Alemtuzumab;mycophenylate mofetil;Hydroxyurea
8 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
9 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
10 A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis Withdrawn NCT00679744 Phase 1 Pyrimethamine
11 Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases Withdrawn NCT01003912 Phase 1
12 Gene Therapy for Tay-Sachs Disease Completed NCT01869270
13 Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. Completed NCT01999257
14 Diagnostic and Screening Study of Genetic Disorders Completed NCT00006057
15 Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders Completed NCT01626092 Campath-1H;Clofarabine;Melphalan;Cyclosporine A;Mycophenolate mofetil
16 A Natural History of Late Onset Tay-Sachs Disease Recruiting NCT02851862
17 A Natural History Study of the Gangliosidoses Recruiting NCT00668187
18 Biomarker for GM1/GM2 - Gangliosidoses Recruiting NCT02298647
19 Nervous System Degeneration in Glycosphingolipid Storage Disorders Recruiting NCT00029965
20 Longitudinal Study of Neurodegenerative Disorders Recruiting NCT03333200

Search NIH Clinical Center for Tay-Sachs Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Tay-Sachs Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: tay-sachs disease

Genetic Tests for Tay-Sachs Disease

Genetic tests related to Tay-Sachs Disease:

# Genetic test Affiliating Genes
1 Tay-Sachs Disease 28 HEXA
2 Tay-Sachs Disease, Pseudo-Ab Variant 28

Anatomical Context for Tay-Sachs Disease

MalaCards organs/tissues related to Tay-Sachs Disease:

38
Testes, Brain, Spinal Cord, Eye, Bone, Retina, Kidney

Publications for Tay-Sachs Disease

Articles related to Tay-Sachs Disease:

(show top 50) (show all 519)
# Title Authors Year
1
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease. ( 28974375 )
2018
2
Late-onset Tay-Sachs disease. ( 28739864 )
2017
3
AAV gene therapy in a sheep model of Tay-Sachs disease. ( 28922945 )
2017
4
Temporary Efficacy of Pyrimethamine in Juvenile-Onset Tay-Sachs Disease Caused by 2 Unreported HEXA Mutations in the Indian Population. ( 28503624 )
2017
5
In silico analyses of essential interactions of iminosugars with the Hex A active site and evaluation of their pharmacological chaperone effects for Tay-Sachs disease. ( 28959811 )
2017
6
Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease. ( 29214523 )
2017
7
NOVEL VECTOR DESIGN AND HEXOSAMINIDASE VARIANT ENABLING SELF-COMPLEMENTARY AAV FOR THE TREATMENT OF TAY-SACHS DISEASE. ( 27197548 )
2016
8
Identification of a patient affected by "Juvenile-chronic" Tay Sachs disease in South Italy. ( 27351546 )
2016
9
CT and MRI findings in a case of infantile form of GM2 gangliosidosis: Tay-Sachs disease. ( 27841233 )
2016
10
Tay-Sachs disease mutations in HEXA target the I+ chain of hexosaminidase A to endoplasmic reticulum-associated degradation. ( 27682588 )
2016
11
Cerebellar atrophy and muscle weakness: late-onset Tay-Sachs disease outside Jewish populations. ( 27033294 )
2016
12
Generation of HEXA-deficient hiPSCs from fibroblasts of a Tay-Sachs disease patient. ( 27879213 )
2016
13
Clinical, biochemical, and molecular findings in a Colombian patient with Tay-Sachs disease. ( 26874567 )
2016
14
Paranoid delusion as lead symptom in two siblings with late-onset Tay-Sachs disease and a novel mutation in the HEXA gene. ( 25860343 )
2015
15
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. ( 26264938 )
2015
16
Mortality incidence estimation using federal death certificate and natality data with an application to Tay-Sachs disease. ( 26080753 )
2015
17
Tay-Sachs disease: current perspectives from Australia. ( 25653550 )
2015
18
Thalamic T2 hypointensity: a diagnostic clue for Tay-Sachs disease. ( 26338066 )
2015
19
Zygosity Diagnosis: When Physicians and DNA Disagree/Twin Research: Sex-Discordant Chimeric Twins; Unrelated Bone Marrow Transplantation in Infant Twins With Congenital Amegakaryotic Thrombocytopenia; Twin Study of Attractiveness to Mosquitoes; Twins Coping With Crisis/Media Highlights: The Less Favored Twin; Paternity Issues; Twins With Late-Onset Tay-Sachs Disease; Triplets at MIT. ( 26323370 )
2015
20
Fundus autofluorescence in Tay-Sachs disease. ( 24852271 )
2014
21
Ashkenazi Jewish population screening for Tay-Sachs disease: The International and Australian experience. ( 24923490 )
2014
22
GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series). ( 25143775 )
2014
23
Three novel mutations in Iranian patients with Tay-Sachs disease. ( 24518553 )
2014
24
Expanding the spectrum of HEXA mutations in Indian patients with Tay-Sachs disease. ( 27896118 )
2014
25
Correlation of augmented startle reflex with brainstem electrophysiological responses in Tay-Sachs disease. ( 24534057 )
2014
26
The first family with Tay-Sachs disease in Cyprus: Genetic analysis reveals a nonsense (c.78G>A) and a silent (c.1305C>T) mutation and allows preimplantation genetic diagnosis. ( 25606403 )
2014
27
Prader-Willi syndrome and Tay-Sachs disease in association with mixed maternal uniparental isodisomy and heterodisomy 15 in a girl who also had isochromosome Xq. ( 25287655 )
2014
28
Choroidal coloboma in a case of tay-sachs disease. ( 25295204 )
2014
29
GM2 gangliosidosis associated with a HEXA missense mutation in Japanese Chin dogs: a potential model for Tay Sachs disease. ( 23266199 )
2013
30
Atypical presentation of Late-Onset Tay-Sachs Disease. ( 24327357 )
2013
31
High school Tay-Sachs disease carrier screening: 5 to 11-year follow-up. ( 23893770 )
2013
32
Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. ( 23230938 )
2012
33
Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India. ( 22723944 )
2012
34
Molecular analysis of HEXA gene in Argentinean patients affected with Tay-Sachs disease: possible common origin of the prevalent c.459+5A>G mutation. ( 22441121 )
2012
35
Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease. ( 22205997 )
2011
36
Tay-Sachs disease preconception screening in Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state better than does ancestral origin, although there is an increased risk for c.1421a88+a881Ga88>a88C mutation in individuals with South African heritage. ( 22109873 )
2011
37
Tay-Sachs disease in an Arab family due to c.78G>A HEXA nonsense mutation encoding a p.W26X early truncation enzyme peptide. ( 21967858 )
2011
38
Identification of two HEXA mutations causing infantile-onset Tay-Sachs disease in the Persian population. ( 21796138 )
2011
39
Tay-Sachs disease in Jacob sheep. ( 20817517 )
2010
40
Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemia. ( 19864874 )
2010
41
Unilaterally and rapidly progressing white matter lesion and elevated cytokines in a patient with Tay-Sachs disease. ( 19278800 )
2010
42
Late-onset Tay-Sachs disease presenting as a childhood stutter. ( 19091716 )
2009
43
Re: Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study. ( 19240988 )
2009
44
'Cherry red spot' in a patient with Tay-Sachs disease: case report. ( 19820796 )
2009
45
Novel human pathological mutations. Gene symbol: HEXA. Disease: Tay-Sachs disease. ( 19644708 )
2009
46
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. ( 19346952 )
2009
47
Serial MR imaging and 1H-MR spectroscopy in monozygotic twins with Tay-Sachs disease. ( 19294598 )
2008
48
Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients. ( 18642377 )
2008
49
Spontaneous appearance of Tay-Sachs disease in an animal model. ( 18693054 )
2008
50
Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study. ( 18618288 )
2008

Variations for Tay-Sachs Disease

UniProtKB/Swiss-Prot genetic disease variations for Tay-Sachs Disease:

71 (show all 49)
# Symbol AA change Variation ID SNP ID
1 HEXA p.Pro25Ser VAR_003202
2 HEXA p.Leu39Arg VAR_003203 rs121907979
3 HEXA p.Leu127Arg VAR_003204 rs121907975
4 HEXA p.Arg166Gly VAR_003205
5 HEXA p.Arg170Gln VAR_003206 rs121907957
6 HEXA p.Arg170Trp VAR_003207 rs121907972
7 HEXA p.Arg178Cys VAR_003208 rs121907953
8 HEXA p.Arg178His VAR_003209 rs28941770
9 HEXA p.Arg178Leu VAR_003210 rs28941770
10 HEXA p.Tyr180His VAR_003211 rs28941771
11 HEXA p.Val192Leu VAR_003212 rs387906310
12 HEXA p.Asn196Ser VAR_003213 rs753862880
13 HEXA p.Lys197Thr VAR_003214 rs121907973
14 HEXA p.Val200Met VAR_003215 rs1800429
15 HEXA p.His204Arg VAR_003216 rs121907976
16 HEXA p.Ser210Phe VAR_003217 rs121907961
17 HEXA p.Phe211Ser VAR_003218 rs121907974
18 HEXA p.Gly250Asp VAR_003221 rs121907959
19 HEXA p.Gly250Ser VAR_003222
20 HEXA p.Arg252His VAR_003223 rs762255098
21 HEXA p.Asp258His VAR_003224 rs121907971
22 HEXA p.Gly269Ser VAR_003225 rs121907954
23 HEXA p.Ser279Pro VAR_003226
24 HEXA p.Met301Arg VAR_003227 rs121907977
25 HEXA p.Ile335Phe VAR_003230
26 HEXA p.Val391Met VAR_003232
27 HEXA p.Trp420Cys VAR_003234 rs121907958
28 HEXA p.Gly454Ser VAR_003236 rs121907978
29 HEXA p.Gly455Arg VAR_003237
30 HEXA p.Cys458Tyr VAR_003238
31 HEXA p.Trp474Cys VAR_003239 rs121907981
32 HEXA p.Glu482Lys VAR_003240 rs121907952
33 HEXA p.Leu484Gln VAR_003241
34 HEXA p.Trp485Arg VAR_003242 rs121907968
35 HEXA p.Arg499Cys VAR_003243 rs121907966
36 HEXA p.Arg499His VAR_003244 rs121907956
37 HEXA p.Arg504Cys VAR_003245 rs28942071
38 HEXA p.Arg504His VAR_003246 rs121907955
39 HEXA p.Arg252Leu VAR_017188
40 HEXA p.Asn295Ser VAR_017189 rs199578185
41 HEXA p.Leu127Phe VAR_022439
42 HEXA p.Ser226Phe VAR_022440 rs769866128
43 HEXA p.Gly269Asp VAR_022441
44 HEXA p.Asp314Val VAR_022442
45 HEXA p.Asp322Asn VAR_077498 rs772180415
46 HEXA p.Asp322Tyr VAR_077499 rs772180415
47 HEXA p.Arg393Pro VAR_077500 rs370266293
48 HEXA p.Glu462Val VAR_077501 rs863225434
49 HEXA p.Gly478Arg VAR_077502 rs1057519467GM2-gangliosidosis

ClinVar genetic disease variations for Tay-Sachs Disease:

6 (show top 50) (show all 98)
# Gene Variation Type Significance SNP ID Assembly Location
1 HEXA NM_000520.5(HEXA): c.173G> A (p.Cys58Tyr) single nucleotide variant Pathogenic rs387906949 GRCh37 Chromosome 15, 72668141: 72668141
2 GM2A NM_000405.4(GM2A): c.333delC (p.Cys112Valfs) deletion Pathogenic rs587779405 GRCh37 Chromosome 5, 150646381: 150646381
3 HEXA NM_000520.5(HEXA): c.1305C> T (p.Tyr435=) single nucleotide variant Pathogenic/Likely pathogenic rs587779406 GRCh37 Chromosome 15, 72638893: 72638893
4 HEXA NM_000520.5(HEXA): c.718_719insT (p.Lys240Ilefs) insertion Pathogenic rs587779407 GRCh37 Chromosome 15, 72642945: 72642946
5 HEXA NM_000520.5(HEXA): c.1528C> T (p.Arg510Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786204585 GRCh37 Chromosome 15, 72636480: 72636480
6 HEXA NM_000520.5(HEXA): c.1307_1308delTA (p.Ile436Serfs) deletion Likely pathogenic rs777042785 GRCh37 Chromosome 15, 72638890: 72638891
7 HEXA NM_000520.5(HEXA): c.1123delG (p.Glu375Argfs) deletion Likely pathogenic rs766138785 GRCh37 Chromosome 15, 72640050: 72640050
8 HEXA NM_000520.5(HEXA): c.986+3A> G single nucleotide variant Pathogenic/Likely pathogenic rs200926928 GRCh38 Chromosome 15, 72349076: 72349076
9 HEXA NM_000520.5(HEXA): c.947dupA (p.Tyr316Terfs) duplication Likely pathogenic rs786204515 GRCh38 Chromosome 15, 72349118: 72349118
10 HEXA NM_000520.5(HEXA): c.915_917delCTT (p.Phe305del) deletion Pathogenic/Likely pathogenic rs121907960 GRCh37 Chromosome 15, 72641489: 72641491
11 HEXA NM_000520.5(HEXA): c.570+1G> A single nucleotide variant Likely pathogenic rs786204754 GRCh37 Chromosome 15, 72645408: 72645408
12 HEXA NM_000520.5(HEXA): c.2T> C (p.Met1Thr) single nucleotide variant Pathogenic/Likely pathogenic rs786204721 GRCh38 Chromosome 15, 72375971: 72375971
13 HEXA HEXA, 2-BP DEL, CODON 310 deletion Pathogenic
14 HEXA NM_000520.5(HEXA): c.1274_1277dup (p.Tyr427Ilefs) duplication Pathogenic rs387906309 GRCh37 Chromosome 15, 72638921: 72638924
15 HEXA NM_000520.5(HEXA): c.1421+1G> C single nucleotide variant Pathogenic rs147324677 GRCh37 Chromosome 15, 72638575: 72638575
16 HEXA NM_000520.5(HEXA): c.-207-2357_253+5128delinsG indel Pathogenic/Likely pathogenic GRCh38 Chromosome 15, 72370592: 72378536
17 HEXA NM_000520.5(HEXA): c.1444G> A (p.Glu482Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121907952 GRCh37 Chromosome 15, 72637869: 72637869
18 HEXA NM_000520.5(HEXA): c.346+1G> C single nucleotide variant Pathogenic/Likely pathogenic rs797044432 GRCh38 Chromosome 15, 72356524: 72356524
19 HEXA NM_000520.5(HEXA): c.1510delC (p.Arg504Alafs) deletion Pathogenic rs797044433 GRCh38 Chromosome 15, 72345462: 72345462
20 HEXA NM_000520.5(HEXA): c.1511G> A (p.Arg504His) single nucleotide variant Pathogenic/Likely pathogenic rs121907955 GRCh37 Chromosome 15, 72637802: 72637802
21 HEXA NM_000520.5(HEXA): c.533G> A (p.Arg178His) single nucleotide variant Pathogenic rs28941770 GRCh37 Chromosome 15, 72645446: 72645446
22 HEXA NM_000520.5(HEXA): c.532C> T (p.Arg178Cys) single nucleotide variant Pathogenic rs121907953 GRCh37 Chromosome 15, 72645447: 72645447
23 HEXA NM_000520.5(HEXA): c.805G> A (p.Gly269Ser) single nucleotide variant Pathogenic rs121907954 GRCh37 Chromosome 15, 72642859: 72642859
24 HEXA NM_000520.5(HEXA): c.1496G> A (p.Arg499His) single nucleotide variant Pathogenic/Likely pathogenic rs121907956 GRCh37 Chromosome 15, 72637817: 72637817
25 HEXA NM_000520.5(HEXA): c.509G> A (p.Arg170Gln) single nucleotide variant Pathogenic rs121907957 GRCh37 Chromosome 15, 72645470: 72645470
26 HEXA NM_000520.5(HEXA): c.1260G> C (p.Trp420Cys) single nucleotide variant Pathogenic rs121907958 GRCh37 Chromosome 15, 72638938: 72638938
27 HEXA NM_000520.5(HEXA): c.409C> T (p.Arg137Ter) single nucleotide variant Pathogenic rs121907962 GRCh37 Chromosome 15, 72647903: 72647903
28 HEXA NM_000520.5(HEXA): c.1177C> T (p.Arg393Ter) single nucleotide variant Pathogenic rs121907963 GRCh37 Chromosome 15, 72639021: 72639021
29 HEXA NM_000520.5(HEXA): c.1510C> T (p.Arg504Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28942071 GRCh37 Chromosome 15, 72637803: 72637803
30 HEXA HEXA, IVS4, G-T, -1 single nucleotide variant Pathogenic
31 HEXA NM_000520.5(HEXA): c.629C> T (p.Ser210Phe) single nucleotide variant Pathogenic rs121907961 GRCh37 Chromosome 15, 72643517: 72643517
32 HEXA HEXA, 5-BP DEL, TCTCC, IVS9 deletion Pathogenic
33 HEXA HEXA, 2-BP DEL, TG, EX5 deletion Pathogenic
34 HEXA NM_000520.5(HEXA): c.78G> A (p.Trp26Ter) single nucleotide variant Pathogenic rs121907964 GRCh37 Chromosome 15, 72668236: 72668236
35 HEXA NM_000520.5(HEXA): c.533G> T (p.Arg178Leu) single nucleotide variant Pathogenic rs28941770 GRCh37 Chromosome 15, 72645446: 72645446
36 HEXA HEXA, IVS2, G-A, +1 single nucleotide variant Pathogenic
37 HEXA NM_000520.5(HEXA): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic rs121907965 GRCh37 Chromosome 15, 72668313: 72668313
38 HEXA NM_000520.5(HEXA): c.1495C> T (p.Arg499Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121907966 GRCh37 Chromosome 15, 72637818: 72637818
39 HEXA NM_000520.5(HEXA): c.1453T> C (p.Trp485Arg) single nucleotide variant Pathogenic rs121907968 GRCh37 Chromosome 15, 72637860: 72637860
40 HEXA HEXA, 1-BP INS insertion Pathogenic
41 HEXA NM_000520.5(HEXA): c.540C> G (p.Tyr180Ter) single nucleotide variant Pathogenic rs121907969 GRCh37 Chromosome 15, 72645439: 72645439
42 HEXA NM_000520.5(HEXA): c.1073+1G> A single nucleotide variant Pathogenic rs76173977 GRCh37 Chromosome 15, 72640388: 72640388
43 HEXA NM_000520.5(HEXA): c.962_964delGAG (p.Gly321del) deletion Pathogenic rs797044434 GRCh38 Chromosome 15, 72349101: 72349103
44 HEXA NM_000520.5(HEXA): c.772G> C (p.Asp258His) single nucleotide variant Pathogenic rs121907971 GRCh37 Chromosome 15, 72642892: 72642892
45 HEXA NM_000520.5(HEXA): c.508C> T (p.Arg170Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121907972 GRCh37 Chromosome 15, 72645471: 72645471
46 HEXA NM_000520.5(HEXA): c.672+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs387906311 GRCh37 Chromosome 15, 72643473: 72643473
47 HEXA NM_000520.5(HEXA): c.632T> C (p.Phe211Ser) single nucleotide variant Pathogenic rs121907974 GRCh37 Chromosome 15, 72643514: 72643514
48 HEXA NM_000520.5(HEXA): c.380T> G (p.Leu127Arg) single nucleotide variant Pathogenic rs121907975 GRCh37 Chromosome 15, 72647932: 72647932
49 HEXA NM_000520.5(HEXA): c.611A> G (p.His204Arg) single nucleotide variant Pathogenic rs121907976 GRCh37 Chromosome 15, 72643535: 72643535
50 HEXA HEXA, 2-BP DEL, TT, CODON 142 deletion Pathogenic

Expression for Tay-Sachs Disease

Search GEO for disease gene expression data for Tay-Sachs Disease.

Pathways for Tay-Sachs Disease

Pathways related to Tay-Sachs Disease according to KEGG:

36
# Name Kegg Source Accession
1 Glycosaminoglycan degradation hsa00531
2 Other glycan degradation hsa00511

GO Terms for Tay-Sachs Disease

Cellular components related to Tay-Sachs Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 ARSA CTSA ETFA GM2A HEXA HEXB
2 lysosome GO:0005764 9.5 ARSA CTSA GM2A HEXA HEXB NEU1
3 azurophil granule lumen GO:0035578 9.46 ARSA CTSA GM2A HEXB
4 azurophil granule GO:0042582 9.32 HEXA HEXB
5 lysosomal lumen GO:0043202 9.17 ARSA CTSA GM2A HEXA HEXB NEU1

Biological processes related to Tay-Sachs Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.73 ARSA CTSA GM2A HEXB NEU1 PSAP
2 metabolic process GO:0008152 9.72 ARSA HEXA HEXB MGEA5 NEU1
3 carbohydrate metabolic process GO:0005975 9.69 HEXA HEXB NEU1
4 positive regulation of catalytic activity GO:0043085 9.54 CTSA GM2A PSAP
5 neuromuscular process controlling balance GO:0050885 9.52 GM2A HEXB
6 sphingolipid metabolic process GO:0006665 9.49 GM2A PSAP
7 lipid storage GO:0019915 9.48 GM2A HEXB
8 hyaluronan catabolic process GO:0030214 9.46 HEXA HEXB
9 chondroitin sulfate catabolic process GO:0030207 9.43 HEXA HEXB
10 keratan sulfate catabolic process GO:0042340 9.4 HEXA HEXB
11 oligosaccharide catabolic process GO:0009313 9.33 GM2A HEXB NEU1
12 glycosphingolipid metabolic process GO:0006687 9.17 ARSA CTSA GM2A HEXA HEXB NEU1
13 ganglioside catabolic process GO:0006689 9.13 GM2A HEXB NEU1

Molecular functions related to Tay-Sachs Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.91 ARSA CTSA GM2A HEXA HEXB MGEA5
2 enzyme activator activity GO:0008047 9.43 CTSA GM2A PSAP
3 acetylglucosaminyltransferase activity GO:0008375 9.4 HEXA HEXB
4 exo-alpha-sialidase activity GO:0004308 9.32 CTSA NEU1
5 hydrolase activity, acting on glycosyl bonds GO:0016798 9.26 HEXA HEXB MGEA5 NEU1
6 N-acetyl-beta-D-galactosaminidase activity GO:0102148 9.16 HEXA HEXB
7 beta-N-acetylhexosaminidase activity GO:0004563 8.8 GM2A HEXA HEXB

Sources for Tay-Sachs Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....